Advertisement

Topics

Bristol-Myers Squibb Announces Empliciti-Based Combination Showed Improvements Across All Efficacy Endpoints in Phase 2 Trial in Multiple Myeloma

10:28 EDT 14 Jun 2019 | Speciality Pharma Journal

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of updated data from ELOQUENT-3, the international randomized Phase 2 study evaluating Empliciti  (elotuzumab) plus pomalidomide and dexamethasone (EPd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM). In a non-prespecified analysis conducted to provide a descriptive assessment …

Original Article: Bristol-Myers Squibb Announces Empliciti-Based Combination Showed Improvements Across All Efficacy Endpoints in Phase 2 Trial in Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb Announces Empliciti-Based Combination Showed Improvements Across All Efficacy Endpoints in Phase 2 Trial in Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...